Tyler Merkeley, MS, MBA, PMP is the co-founder of CARB-X and serves as the Biomedical Advanced Research and Development Authority’s (BARDA) CARB-X Program Manager. Mr. Merkeley joined the Department of Health and Human Services (HHS), BARDA in 2009 as a Health Scientist in an effort to accelerate the advanced research and development, procurement, stockpile and sustainment of medical countermeasures (MCM) against biological, chemical, radiological, and nuclear (CBRN) agents under Project BioShield. During his tenure at BARDA, he has supported various initiatives including BARDA’s Total Life Cycle Costs containment initiative, designing and launching HHS’s Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator [CARB-X] and managing BARDA’s 1st agreement using Other Transaction Authority (OTA).
Prior to his transition to lead BARDA’s CARB-X initiative, he served as Acting Chief of Staff for BARDA and previously as a Health Scientist in BARDA’s Antibacterial Program. In 2010, Mr. Merkeley assisted in the strategic planning and launch of BARDA’s Antibacterial Program with the goal to revitalize the antibiotic development pipeline so that critically needed novel antibiotics are developed to treat an increasing number of antibiotic resistant infections. Over the last 6 years, Mr. Merkeley assisted in the strategic direction and growth of the Antibacterial portfolio from an initial vision in 2010 to a $1.4 billion portfolio with 7 public private partnerships. While a member of the Antibacterial Program, Mr. Merkeley also led two integrated matrix teams overseeing a portfolio in excess of $700 Million for novel antibacterial and antiviral candidates. Mr. Merkeley was responsible for leading and assembling public private partnerships with SIGA Technologies Inc. and GlaxoSmithKline (GSK) including the interagency effort that successfully delivered a smallpox antiviral drug to the Strategic National Stockpile (SNS). In 2016, Mr. Merkeley served as the Acting Chief of Staff for BARDA during a leadership transition, working to improve internal efficiencies, execute over $1 billion in annual funding and manage a portfolio in excess of $5 billion.
Prior to BARDA, Mr. Merkeley was an international team member with the U.S. Department of Defense’s Biological Threat Reduction Program (BTRP) in Kazakhstan. The BTRP program supports the planning, design, implementation, and maintenance of Kazakhstan’s public health infrastructure. Mr. Merkeley was responsible for providing scientific subject matter expertise and program management support. Mr. Merkeley received his Masters of Science in Biohazard Threat Agents and Emerging Infectious Diseases from Georgetown University and his Masters of Business Administration (MBA) in Finance and International Business from Iona College in New York.